This section of the site includes press releases and statements issued by the MHRA.
The opening hours for the Press Office are Monday to Friday between 9:00 and 17:00.
The Press Office
151 Buckingham Palace Road
Main telephone: 020 3080 7651
Out of hours: 07770 446 189
For urgent calls outside these press office hours please contact the duty press officer on : 07770 446 189.
We now have a Twitter channel for press releases and news statements, giving you another way to find out the latest news from the MHRA in real time.
Press enquiries should be made through the Press Office.
Latest press releases
24 Jul 2014 | Press release: European review concludes positive benefit risk of emergency contraceptives
Emergency contraceptives continue to be suitable for all women who need them, regardless of the woman’s weight said the Medicines and Healthcare products Regulatory Agency (MHRA) today. These medicines may continue to be used to prevent unintended pregnancies and should be taken as soon as possible after unprotected intercourse or contraceptive failure. This follows a European review that concluded that the benefits of emergency contraceptives continue to outweigh the risks in all women.
People using fentanyl skin (‘transdermal’) patches and their carers should check that the patches are stuck on securely and are disposed of safely. This follows reports to the Medicines and Healthcare products Regulatory Agency (MHRA) of these patches accidentally sticking to other people’s skin on contact.
18 Jul 2014 | New independent expert advisory group to be created as the MHRA responds to Stephenson review
MHRA today announced that a new independent Devices Expert Advisory Committee (DEAC) will be established before April 2015 and will be responsible for providing independent expert advice that helps the MHRA regulate medical devices such as hips, breast implants and pacemakers.
16 Jul 2014 | Press release: Continuation of whooping cough vaccination programme for pregnant women advised as new evidence on effectiveness and safety published
Public Health England (PHE) welcomes today’s announcement from the Joint Committee on Vaccination and Immunisation (JCVI) advising the Department of Health (DH) that the whooping cough (pertussis) vaccination programme for pregnant women should continue for a further 5 years. The advice reflects new data on vaccine effectiveness and safety published by PHE and MHRA.
01 Jul 2014 | Press statement: Bacillus cereus infections: 1 July 2014
Since the last update on 12 June 2014, a further case in the outbreak of Bacillus cereus has been identified and the total number of cases linked to this investigation is 23 (19 confirmed and 4 possible cases). This baby has sadly died and our thoughts are with the family.
12 Jun 2014 | Press statement: Update on investigation into Bacillus cereus infections: 12 June 2014
Public Health England (PHE) can report the total number of cases linked to its investigation of blood poisoning (septicaemia) in England stands at 22 (18 confirmed and four possible cases). All cases received the potentially affected intravenous liquid (total parental nutrition, TPN).
MHRA is asking people with diabetes who use Accu-Chek® Mobile blood glucose meters to ensure they follow the important testing instructions. This is because the meter may give false high blood glucose readings if testing instructions are not followed accordingly.
06 Jun 2014 | Press statement: Joint PHE and MHRA update on investigation into Bacillus cereus infections
Public Health England (PHE) can report that three further cases of blood poisoning (septicaemia) in babies being treated in neonatal intensive care units in England, have been identified after looking back at clinical records. These babies received the potentially affected batches of intravenous liquid before Tuesday 3 June, when the affected stock expired. This takes the total number of cases to 21, with one death.
Public Health England (PHE) can report three further cases of blood poisoning (septicaemia) in babies at neonatal intensive care units in England who had received the potentially affected batches of intravenous liquid, taking the total number of cases to 18, with one death. MHRA is continuing its investigation into this incident and the manufacturer is co-operating fully.